<DOC>
	<DOCNO>NCT00686036</DOCNO>
	<brief_summary>The purpose study determine whether treatment Zactima 18 month prolong off-treatment interval patient undergoing intermittent androgen deprivation therapy .</brief_summary>
	<brief_title>Trial Assessing Zactima Against Placebo Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Diagnosis prostate cancer Prostate specific antigen ( PSA ) great equal 5 ng/mL Recent completion first hormone treatment [ intermittent androgen deprivation Luteinising hormone release hormone ( LHRH ) analogue ] Screening PSA â‰¤1.0 ng/mL ( within 6 week prior study Day1 ) Bone soft tissue metastasis Significant cardiovascular disease include hypertension control medical therapy history irregular heart beat recent heart attack</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>hormone treatment</keyword>
</DOC>